A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2008
At a glance
- Drugs Capecitabine; Ispinesib
- Indications Solid tumours
- Focus Adverse reactions
- 30 Jun 2008 Results announced in a Cytokinetics media release (9090632).
- 30 Jun 2008 Status changed from in progress to completed, as reported by Cytokinetics.
- 29 Apr 2008 Cytokinetics has reported that final results are expected to be available in the second half of 2008.